Accelerating patient access to innovative treatments that improve quality of life
Correct study choice and effective execution are paramount to achieving your goals. We design and implement studies to collect real world data, with a focus on maximising the return on investment.
Our integrated team of 300+ industry experts provides life-science clients with strategic guidance and workable tactical solutions to support brand success around the globe.
ICON delivers Commercialisation & Outcomes services, resources and expertise to identify, generate, synthesize and communicate evidence of treatment value and safety, to help regulators, payers, providers and patients make informed health decisions.
Our global epidemiologists and outcomes researchers employ Real World Intelligence, combining real world data, advanced technology and deep expertise to accelerate market access
We understand the unique requirements of managing late phase and post-market studies. Our innovative global research services hubs deliver end-to-end site and patient support and patient engagement.
As the industry’s largest life sciences language services provider, we deliver translations, linguistic validations, and market dominant COA expertise.
Today’s regulatory landscape is complex and ever-changing. We deliver solutions built on 30+ years of experience navigating global regulatory requirements and emerging issues.
ICON is the leading sponsor of Mapi Research Trust, a non-profit organisation dedicated to improving patients’ quality of life by facilitating access to patient-centered outcome information
Get the information and insights you need to stay fully informed about developments in global healthcare systems, important pricing and reimbursement trends and policies, and advances in key therapeutic areas. Receive future issues of our briefing.Subscribe to our newsletter
Download our latest issue to explore insights, information, and analysis on payer trends & drivers of market access success, pricing policy and regulations in key markets, regulatory agency requirements and policies that govern market approval, and the impact on reimbursement decisions innovative therapeutic advancements.